TP53 and breast cancer: This study demonstrates that Ell3 induces a chemosensitive response in breast cancer cell line MCF7, by suppressing the MDM2-mediated pathway of p53 ubiquitination and increasing the binding of p53 to NQO1 after CDDP treatment (Figure 6).